The Vanguard Group's Disclosure on Avadel Pharmaceuticals Securities

The Vanguard Group, Inc. has made an important disclosure regarding its interests in Avadel Pharmaceuticals plc under Rule 8.3 of the Irish Takeover Panel Act, 1997. This disclosure, dated 22 December 2025, is a part of the opening position and dealing disclosure requirements. It reveals that Vanguard holds 5,868,015 US$0.01 ordinary shares in Avadel Pharmaceuticals, representing a 6.02% interest.

The documentation highlights purchases and sales of securities, with 56,031 shares purchased and 12,877 shares sold, both at a unit price of 21.47 USD. No cash-settled or stock-settled derivative transactions are reported, and there are no other agreements or arrangements affecting voting rights or future acquisitions.

This disclosure provides a transparent look into Vanguard's securities position in Avadel Pharmaceuticals, while adhering to regulatory requirements.